Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
A new study reveals that blocking the macrophage EP2 receptor restores cell clearance and reverses systemic multi-organ aging ...
Researchers from Heinrich Heine University Düsseldorf (HHU) and Kiel University (CAU) have examined immune system function in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results